Administrative Burden as a Potential Cause of Financial Hardship and Poor Mental Health in Cancer: A Mixed Methods Study [0.03%]
一项混合研究方法研究：行政负担可能是癌症患者经济困难和心理健康不良的潜在原因
Salene M W Jones,Kendall Harkey,Ananya Vaidyaraman et al.
Salene M W Jones et al.
Purpose: Administrative burdens are the extra steps a person must take to receive benefits from an institution. Examples include prior authorizations, denials of coverage, complex leave and accommodation policies, and pap...
Alicia H Darwin,James C Dickerson,Pauline Funchain
Alicia H Darwin
Cutaneous melanoma management has been revolutionized by immunotherapy. Immune checkpoint inhibitors, first approved for melanoma in 2011, have become a mainstay in melanoma management. More recently, tumor infiltrating lymphocyte therapy h...
George W Sledge Jr
George W Sledge Jr
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy [0.03%]
针对辅助抗PD-1治疗的高危可切除黑色素瘤患者中关于输注时间分析偏倚的研究：NCI/SWOG S1404试验
Megan Othus,Thach-Giao Truong,Elad Sharon et al.
Megan Othus et al.
Purpose: Multiple reports have suggested that receiving immunotherapy infusions earlier in the day is associated with improved outcomes, including longer overall survival (OS) and lower toxicity rates. However, the defini...
Bridging the Gap: Examining the Association of Travel Burden With Treatment Administration and Survival in Stage II/III Gastric Cancer [0.03%]
桥梁工程：检查旅行负担与II/III期胃癌治疗管理和生存率之间的关联
Asimina Courelli,Lola Van Doosselaere,Lailie Kahsai et al.
Asimina Courelli et al.
Purpose: Travel burden has been identified as a source of care disparities in other malignancies, but its impact on gastric cancer care is poorly understood. Therefore, we investigated the impact of travel burden on treat...
Competencies for Clinical Leadership in Oncology: A Framework for Cancer Department Governance [0.03%]
肿瘤学临床领导力的核心胜任力：癌症部门管理框架
Mauro Iannopollo
Mauro Iannopollo
Medicare Advantage and Oncology Care: Considerations for Patients and Clinicians [0.03%]
医疗保险优势和肿瘤护理：患者和临床医生的考虑因素
Tricia Neuman,Jean Fuglesten Biniek,Abby Wolk
Tricia Neuman
Timeliness of Prostate Cancer Treatment in Medicare Advantage and Traditional Medicare: More Similarities than Differences? [0.03%]
医疗保险优势计划和传统医疗保险前列腺癌治疗的及时性：相似之处多于差异？
Aaron P Mitchell,Nancy L Keating
Aaron P Mitchell
Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors [0.03%]
顺铂致儿童癌症幸存者听力损失对其生活质量的影响
Michael Migotsky,Ramon Durazo-Arvizu,David R Freyer et al.
Michael Migotsky et al.
Purpose: Cisplatin-based chemotherapy is essential to treat many childhood cancers but causes irreversible hearing loss (HL). This study examines hearing-related quality of life (HR-QOL) in cisplatin-treated pediatric can...
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis [0.03%]
培美曲塞/派姆单抗与派姆单抗维持治疗非小细胞肺癌的疗效：倾向性评分加权分析
Garth W Strohbehn,Molly C Tokaz,Daniel Sanghoon Shin et al.
Garth W Strohbehn et al.
Purpose: Pemetrexed remains part of guideline-recommended maintenance pemetrexed/pembrolizumab in advanced/metastatic non-oncogene-driven nonsquamous non-small cell lung cancer (NSCLC). Whether pemetrexed contributes to t...